Picture EBD Group BioPharm America 2018 Boston September 600x60px
Document › Details

Eurofins Scientific. (3/7/14). "Press Release: Eurofins Strengthens Its European Environmental Testing Market Leadership with the Acquisition of Omegam in the Netherlands".

Region Region Netherlands
Organisations Organisation Eurofins Scientific SE (EUFI.PA)
  Group Eurofins (Group)
  Organisation 2 Omegam Laboratoria B.V.
  Group Eurofins (Group)
Products Product environmental analysis
  Product 2 water analysis services
Index term Index term Omegam Laboratoria–Eurofins: investment, 201403 acquisition by Eurofins
Person Person Martin, Gilles G. (Eurofins 200701 CEO + founder)

Eurofins Scientific (EUFI.PA), the world leader in analytical testing support to the global environmental sector, announces the acquisition of Omegam Laboratoria BV (Omegam), one of the leading independent laboratories in The Netherlands for environmental and water testing.

With a large, modern laboratory strategically located close to Schiphol Airport, Omegam employs more than 100 staff and generates over EUR 10m in revenues. Formerly Amsterdam's water quality control board, Omegam has built more than 30 years of expertise in the analysis of trace level components in water and soil. It is the local private market leader in specialized fields of water testing, in particular, the analyses of pesticides, hormones and drug residues.

The acquisition reinforces Eurofins' leadership in the environmental testing market in the Benelux, and strengthens the Group's service offering to cover the full spectrum of water analysis, specifically in helping clients comply with the EU Water Framework Directive1, a current industry priority ahead of the 2015 deadline for progress report. Furthermore, it strengthens the Group's platform as the only privately-owned laboratory in the domestic water testing market, currently still dominated by public laboratories as well as in-house laboratories of drinking water companies.

Comment from Dr. Gilles Martin, Eurofins CEO: "This acquisition reflects Eurofins' strategy of consolidating the markets where we are active in, and ensuring that we have the depth and breadth of competencies required to provide the best service to our clients. We are looking forward to leveraging our strengthened position in the environmental and water testing market in The Netherlands with the addition of Omegam into our network."

1 For details regarding the EU Water Framework Directive, please refer to

For more information, please visit or contact:

Eurofins Investor Relations
Phone: +32-2-766 1620

Notes for the editor:

Eurofins - a global leader in bio-analysis

Eurofins Scientific is the world leader in food and pharmaceutical products testing. It is also number one in the world in the field of environmental laboratory services and one of the global market leaders in agroscience, genomics, discovery pharmacology and central laboratory services.

With about 15,000 staff in more than 190 laboratories across 36 countries, Eurofins offers a portfolio of over 100,000 reliable analytical methods for evaluating the safety, identity, composition, authenticity, origin and purity of biological substances and products. The Group provides its customers with high-quality services, accurate results in time and expert advice by its highly qualified staff.

Eurofins is committed to pursuing its dynamic growth strategy by expanding both its technology portfolio and its geographic reach. Through R&D and acquisitions, the Group draws on the latest developments in the field of biotechnology and analytical chemistry to offer its clients unique analytical solutions and the most comprehensive range of testing methods.

As one of the most innovative and quality oriented international players in its industry, Eurofins is ideally positioned to support its clients' increasingly stringent quality and safety standards and the expanding demands of regulatory authorities around the world.

The shares of Eurofins Scientific are listed on the NYSE Euronext Paris Stock Exchange (ISIN FR0000038259, Reuters EUFI.PA, Bloomberg ERF FP).

Important disclaimer: This press release contains forward-looking statements and estimates that involve risks and uncertainties. The forward-looking statements and estimates contained herein represent the judgement of Eurofins Scientific' management as of the date of this release. These forward-looking statements are not guarantees for future performance, and the forward-looking events discussed in this release may not occur. Eurofins Scientific disclaims any intent or obligation to update any of these forward-looking statements and estimates. All statements and estimates are made based on the information available to the Company's management as of the date of publication, but no guarantee can be made as to their validity.

Updated by: bdqu
Last updated: 07 March 2014

Record changed: 2016-01-10


Picture EBD Group Biotech Showcase 2019 San Francisco BTS January 600x60px

More documents for Eurofins (Group)

To subscribe to our free, monthly mass spectrometry newsletter, please send an e-mail to and simply fill the subject line with the word »MSC Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the Eurpean life sciences and the life sciences in German-speaking Europe (DE, AT & CH) at and


Picture EBD Group ChinaBio Partnering Forum 2019 Shanghai CBPF May 600x60px

» top